{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:34:56Z","timestamp":1789940096894,"version":"4.0.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,12]]},"DOI":"10.1093\/ibd\/izy129","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T08:46:03Z","timestamp":1526633163000},"page":"1745-1754","source":"Crossref","is-referenced-by-count":24,"title":["Modeling Immunization To Infliximab in Children With Crohn\u2019s Disease Using Population Pharmacokinetics: A Pilot Study"],"prefix":"10.1093","volume":"24","author":[{"given":"Antoine","family":"Petitcollin","sequence":"first","affiliation":[{"name":"Pharmacoepidemiology and Drug Information Center, Department of Clinical and Biological Pharmacology and Pharmacovigilance, Rennes University Hospital, Rennes, France"},{"name":"Laboratory of Experimental and Clinical Pharmacology, Faculty of Medicine, Rennes 1 University, Rennes, France"},{"name":"CIC-P 1414 Clinical Investigation Center, Inserm, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriane","family":"Leuret","sequence":"additional","affiliation":[{"name":"Paediatric Medicine Unit, Tours University Hospital, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Tron","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Drug Information Center, Department of Clinical and Biological Pharmacology and Pharmacovigilance, Rennes University Hospital, Rennes, France"},{"name":"Laboratory of Experimental and Clinical Pharmacology, Faculty of Medicine, Rennes 1 University, Rennes, France"},{"name":"CIC-P 1414 Clinical Investigation Center, Inserm, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lemaitre","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Drug Information Center, Department of Clinical and Biological Pharmacology and Pharmacovigilance, Rennes University Hospital, Rennes, France"},{"name":"Laboratory of Experimental and Clinical Pharmacology, Faculty of Medicine, Rennes 1 University, Rennes, France"},{"name":"CIC-P 1414 Clinical Investigation Center, Inserm, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Cl\u00e9mence","family":"Verdier","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Drug Information Center, Department of Clinical and Biological Pharmacology and Pharmacovigilance, Rennes University Hospital, Rennes, France"},{"name":"Laboratory of Experimental and Clinical Pharmacology, Faculty of Medicine, Rennes 1 University, Rennes, France"},{"name":"CIC-P 1414 Clinical Investigation Center, Inserm, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Paintaud","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology-Toxicology, CNRS, GICC UMR 7292, Tours University Hospital, Fran\u00e7ois-Rabelais University of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bouguen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Rennes University Hospital, Rennes, France"},{"name":"CIC-P 1414 Clinical Investigation Center, Inserm U991, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Willot","sequence":"additional","affiliation":[{"name":"Paediatric Medicine Unit, Tours University Hospital, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bellissant","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Drug Information Center, Department of Clinical and Biological Pharmacology and Pharmacovigilance, Rennes University Hospital, Rennes, France"},{"name":"Laboratory of Experimental and Clinical Pharmacology, Faculty of Medicine, Rennes 1 University, Rennes, France"},{"name":"CIC-P 1414 Clinical Investigation Center, Inserm, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ternant","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology-Toxicology, CNRS, GICC UMR 7292, Tours University Hospital, Fran\u00e7ois-Rabelais University of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,18]]},"reference":[{"key":"key\n\t\t\t\t20180712110057_CIT0001","first-page":"833","article-title":"The impact of therapeutic antibodies on the management of digestive diseases: history, current practice, and future directions","volume":"62","author":"Sofia","year":"2017","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20180712110057_CIT0002","first-page":"40","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180712110057_CIT0003","first-page":"601","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180712110057_CIT0004","first-page":"1","article-title":"Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"O\u2019Meara","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180712110057_CIT0005","first-page":"580","article-title":"Infliximab optimization based on therapeutic drug monitoring in pediatric inflammatory bowel disease","volume":"64","author":"Hofmekler","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key\n\t\t\t\t20180712110057_CIT0006","first-page":"1474","article-title":"Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy","volume":"12","author":"Baert","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180712110057_CIT0007","first-page":"1359","article-title":"Effects of combination therapy with immunomodulators on trough levels and antibodies against tumor necrosis factor antagonists in patients with inflammatory bowel disease: a meta-analysis","volume":"15","author":"Qiu","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180712110057_CIT0008","first-page":"650","article-title":"A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180712110057_CIT0009","first-page":"1861","article-title":"Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180712110057_CIT0010","first-page":"1320","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180712110057_CIT0011","first-page":"161","article-title":"Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade\u00ae","volume":"19","author":"Marini","year":"2017","journal-title":"Aaps J"},{"key":"key\n\t\t\t\t20180712110057_CIT0012","first-page":"169","article-title":"An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab","volume":"28","author":"Ternant","year":"2006","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20180712110057_CIT0013","first-page":"383","article-title":"IgG1 heavy chain-coding gene polymorphism (G1M allotypes) and development of antibodies-to-infliximab","volume":"19","author":"Magdelaine-Beuzelin","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"key\n\t\t\t\t20180712110057_CIT0014","first-page":"529","article-title":"Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice","volume":"42","author":"Buurman","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180712110057_CIT0015","first-page":"946","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20180712110057_CIT0016","first-page":"1918","article-title":"Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia","volume":"52","author":"Li","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180712110057_CIT0017","first-page":"e144","article-title":"Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin\u2019s lymphoma and exposure-response in CLL","volume":"3","author":"Gibiansky","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"key\n\t\t\t\t20180712110057_CIT0018","first-page":"58","article-title":"Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"key\n\t\t\t\t20180712110057_CIT0019","first-page":"1211","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180712110057_CIT0020","first-page":"251","article-title":"Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis","volume":"14","author":"Brandse","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180712110057_CIT0021","first-page":"R105","article-title":"Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases","volume":"13","author":"Ducourau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180712110057_CIT0022","first-page":"41","article-title":"The immunogenic part of infliximab is the F(ab\u2019)2, but measuring antibodies to the intact infliximab molecule is more clinically useful","volume":"60","author":"Ben-Horin","year":"2011","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180712110057_CIT0023","first-page":"1407","article-title":"The underlying inflammatory chronic disease influences infliximab pharmacokinetics","volume":"8","author":"Passot","year":"2016","journal-title":"Mabs"},{"key":"key\n\t\t\t\t20180712110057_CIT0024","first-page":"286","article-title":"Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis","volume":"79","author":"Ternant","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180712110057_CIT0025","first-page":"1155","article-title":"Pharmacokinetics of adalimumab in Crohn\u2019s disease","volume":"71","author":"Ternant","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180712110057_CIT0026","first-page":"1513","article-title":"Accounting for pharmacokinetic variability of certolizumab pegol in patients with Crohn\u2019s disease","volume":"56","author":"Vande Casteele","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180712110057_CIT0027","first-page":"3782","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/8\/1745\/25154030\/izy129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T12:34:39Z","timestamp":1531398879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/8\/1745\/4999391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,18]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,5,18]]},"published-print":{"date-parts":[[2018,7,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy129","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,5,18]]}}}